Core Insights - Chengdu Xian Dao reported a significant increase in revenue and profit for the first half of 2025, with total revenue reaching 227 million yuan, a year-on-year growth of 16.58%, and a net profit attributable to shareholders of 50.04 million yuan, up 390.72% [2][3] Financial Performance - The company achieved a net cash flow from operating activities of 111 million yuan, reflecting a year-on-year increase of 51.48% [2] - The overall gross margin for the main business was 53.82%, an increase of 7.23 percentage points compared to the previous year [2] Business Segments - The DEL segment, a cornerstone of Chengdu Xian Dao's business, generated revenue of 102 million yuan, marking a growth of 40.45% [3] - The UK subsidiary Vernalis confirmed milestone revenue, contributing to the steady development of the FBDD/SBDD platform [3] - The OBT segment expanded its traditional nucleoside monomer synthesis business while achieving commercial transformation of small nucleic acid one-stop projects [3] - The TPD segment actively explored new business models and initiated new project collaborations based on PROTAC technology [3] - The ChemSer segment saw a remarkable revenue increase of 94.17% due to the efficient operation of the automated high-throughput chemical synthesis platform [3] Market Strategy - The company is leveraging a global perspective to deepen collaborations and optimize international market strategies, enhancing operational efficiency and market positioning [3] - Chengdu Xian Dao is committed to advancing its technological platforms and research projects while exploring commercialization opportunities [3] Leadership Perspective - The CEO, Dr. Li Jin, emphasized the company's ongoing positive development and commitment to innovation-driven growth, aiming to create sustainable value for shareholders, clients, and society [4]

Core Viewpoint - Chengdu Xian Dao (688222) reported significant growth in revenue and profit for the first half of 2025, indicating a strong performance in the pharmaceutical R&D sector, particularly in small molecules and nucleic acid drugs [1][2]. Financial Performance - The company achieved operating revenue of 227 million yuan, a year-on-year increase of 16.58% [1] - Net profit reached 50.04 million yuan, up 390.72% year-on-year [1] - The net profit after deducting non-recurring items was 53.91 million yuan, reflecting a substantial increase of 2517.66% [1] - The net cash flow from operating activities was 111 million yuan, growing by 51.48% [1] - The overall gross margin for the main business was 53.82%, an increase of 7.23 percentage points year-on-year [1] Business Segments and Growth - Chengdu Xian Dao focuses on four core technology platforms: DEL technology, FBDD/SBDD, OBT, and TPD, which support its drug discovery and optimization capabilities [1][2] - The DEL segment, which includes the design, synthesis, and screening of DEL libraries, generated revenue of 102 million yuan, a year-on-year increase of 40.45% [2] - The OBT segment expanded its traditional nucleoside monomer synthesis business while achieving commercial transformation of small nucleic acid projects [3] - The TPD segment actively explored new business models and initiated new project collaborations based on PROTAC technology [3] Market Strategy and Resource Allocation - The company is leveraging domestic and international resources to optimize its market strategy and meet diverse customer demands [2] - Chengdu Xian Dao's UK subsidiary, Vernalis, confirmed milestone revenue during the reporting period, supporting the steady development of the FBDD/SBDD platform [2] - The company reported a 94.17% year-on-year increase in revenue from ChemSer services, driven by the efficient operation of its automated high-throughput chemical synthesis platform [3] - R&D investment increased year-on-year, while Vernalis adjusted its resource allocation to focus on commercial projects, resulting in a slight decrease in overall R&D expenses [3]

Core Viewpoint - Chengdu Xian Dao announced an incentive plan to grant 115 individuals a total of 1,052,200 restricted stocks, representing approximately 0.26% of the company's total share capital of about 401 million shares [1] Summary by Relevant Sections - **Incentive Plan Details** - The incentive plan involves granting restricted stocks to 115 individuals, sourced from shares repurchased in the secondary market or newly issued shares [1] - The total number of restricted stocks to be granted is 1,052,200 [1] - The grant price for the restricted stocks is set at 13.99 yuan per share [1] - **Stock Ownership and Conditions** - The restricted stocks represent about 0.26% of the company's total share capital at the time of the announcement [1] - The effective period for the restricted stocks is from the grant date until the stocks are fully vested or become invalid, with a maximum duration of 36 months [1]

Group 1 - The core viewpoint of the articles highlights Chengdu XianDao's strong performance in the first half of 2025, with significant growth in revenue, net profit, and gross margin [1][2] - Chengdu XianDao achieved an operating income of 227 million yuan, a year-on-year increase of 16.58% [1] - The net profit attributable to shareholders reached 50.042 million yuan, reflecting a remarkable year-on-year growth of 390.72% [1] - The net profit after deducting non-recurring gains and losses was 53.912 million yuan, showing a substantial increase of 2517.66% year-on-year [1] - The net cash flow from operating activities was 111 million yuan, up by 51.48% compared to the previous year [1] - The overall gross margin for the main business was 53.82%, an increase of 7.23 percentage points year-on-year [1] Group 2 - Chengdu XianDao is actively seizing market opportunities and enhancing cooperation with a global perspective, optimizing international market strategies [1] - The company has made structural adjustments to R&D investments to maintain innovation capabilities while improving resource allocation efficiency [1] - Chengdu XianDao has established an ESG work system based on international and domestic standards and published its first bilingual sustainability report [1] - The Chairman and CEO, Li Jin, emphasized the company's commitment to innovation-driven development and creating sustainable value for shareholders, customers, and society [2]

Core Viewpoint - The company is set to implement a restricted stock incentive plan for 2025, which has been reviewed and approved by the Board's Compensation and Assessment Committee, ensuring compliance with relevant laws and regulations [1][3]. Group 1: Compliance and Eligibility - The company does not have any circumstances that prohibit the implementation of the stock incentive plan as per the relevant laws and regulations [1]. - The identified incentive recipients meet all eligibility criteria and do not fall under any disqualifying conditions set by regulatory authorities [2][3]. Group 2: Plan Details and Approval Process - The drafting and review process of the incentive plan aligns with the requirements of the Company Law, Securities Law, and other relevant regulations, ensuring that the plan does not infringe on the interests of the company or its shareholders [3]. - The plan requires approval from the shareholders' meeting before implementation [3]. Group 3: Benefits and Mechanism - The implementation of the incentive plan is expected to enhance the company's incentive mechanism, improve the distribution system that combines incentives and constraints, and effectively boost the cohesion of the core team and the company's core competitiveness [3].

Core Points - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. held its 23rd meeting of the second board of directors on August 26, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved several key proposals, including the review of the 2025 semi-annual report and the special report on the use of raised funds [2][3] - The board also approved the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][3] - The board nominated candidates for the third board of directors, including both non-independent and independent directors, pending shareholder approval [3][4] - The board reviewed and approved the semi-annual evaluation report of the 2025 quality improvement and efficiency recovery action plan [4] - The board discussed the 2025 restricted stock incentive plan and its management methods, which will also require shareholder approval [5][6] - The board proposed to authorize the board to handle matters related to the 2025 employee stock ownership plan, pending shareholder approval [8][9]

（一）最近 12 个月内被证券交易所认定为不适当人选； 成都先导药物开发股份有限公司监事会 关于 2025 年限制性股票激励计划相关事项的核查意见 成都先导药物开发股份有限公司（以下简称"公司"）监事会依据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称 "《上市规则》"）、《科创板上市公司自律监管指南第 4 号－－股权激励信 息披露》等相关法律、法规及规范性文件和《成都先导药物开发股份有限公司 章程》（以下简称"《公司章程》"）的规定，对公司 2025 年限制性股票激励 计划（以下简称"本次激励计划"）相关事项进行了核查，发表核查意见如下： 一、公司不存在《管理办法》等法律、法规规定的禁止实施股权激励计划 的情形，包括： （一）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无 法表示意见的审计报告； （二）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或 无法表示意见的审计报告； （三）上市后最近 36 个月内出现过未按法律 ...

Meeting Overview - The second meeting of the Supervisory Board of Chengdu XianDao Pharmaceutical Development Co., Ltd. was held on August 26, 2025, with all three supervisors present [1] - The meeting was convened in accordance with relevant laws and regulations, and the resolutions passed were deemed legal and effective [1] Resolutions Passed - The Supervisory Board approved the company's 2025 semi-annual report and its summary [2] - The board also approved the special report on the storage and actual use of the raised funds for the first half of 2025 [2] - A resolution was passed to cancel the Supervisory Board, amend the company’s articles of association, and remove the chairman of the Supervisory Board, pending approval from the shareholders' meeting [2][3] - The board approved the draft of the 2025 restricted stock incentive plan and its summary, which will also be submitted for shareholder approval [3] - The implementation assessment management measures for the 2025 restricted stock incentive plan were approved, pending shareholder approval [3] - The verification of the list of incentive objects for the 2025 restricted stock incentive plan was also approved [3] - The draft of the 2025 employee stock ownership plan and its summary could not be resolved due to two supervisors abstaining from voting, and it will be submitted for shareholder approval [4] - The management measures for the 2025 employee stock ownership plan could not be resolved for the same reason and will also be submitted for shareholder approval [4]

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 15, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1][2] - The on-site meeting will take place at the company's conference room in Chengdu [1] Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system during specified trading hours on the meeting day [1][3] - Specific voting procedures apply to margin trading, transfer, and other related accounts [2] Agenda Items - The meeting will review 10 proposals, including amendments to the company's articles of association and management assessment methods [3] - Related announcements were disclosed on August 28, 2025, on the Shanghai Stock Exchange website and various financial newspapers [3] Attendance Requirements - Shareholders must be registered by the close of trading on September 8, 2025, to attend the meeting [4] - Registration for attendance requires valid identification and proof of share ownership [5][6] Contact Information - The company has provided contact details for inquiries regarding the meeting [6]

Core Viewpoint - Chengdu XianDao announced a revenue of 227 million yuan for the first half of 2025, representing a year-on-year growth of 16.58% [1] - The net profit attributable to shareholders reached 50.042 million yuan, showing a significant year-on-year increase of 390.72% [1] - Basic earnings per share stood at 0.12 yuan, reflecting a remarkable year-on-year growth of 500% [1]